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INTRODUCTION 
Tuberculosis or TB is the most common infectious disease. In the past 
Tuberculosis also called  as phthisis or  phthisis pulmonalis. TB is second 
only to HIV/AIDS as the greatest killer worldwide due to a single infectious 
agent.
(1)
  In addition, the prevalence of drug-resistant TB is also  increasing 
worldwide. Co-infection with HIV has been an important factor in the 
emergence and spread of resistance. 
(2)
 New TB treatments are being 
developed and new vaccines are currently under investigation. 
(3)
 TB is a 
major global health threat, and there is need to  improve the existing 
treatment regimen to control the spread of TB.   
Tuberculosis is an airborne disease.  It is spread from person to person 
through the air (vehicle).Tuberculosis is most often affect the lungs.
(4)  
 
HISTORY 
Tuberculosis is the second deadliest disease (first HIV/AIDS). The 
World Health Organization estimates, that 2 billion people have latent TB, 
while another 3 million people worldwide die of TB in every year. In 2013, 
8.2 million peoples fell ill with TB and 1.2 million peoples died. 
(5) 
Figure 1
(6) 
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TUBERCULOSIS  
 
M. tuberculosis and seven very closely related mycobacterial species 
(M. bovis, M.  africanum, M. microti, M. caprae, M. pinnipedii, M. canetti 
and M. mungi) together comprise  what is known as the M. tuberculosis 
complex. Most, but not all, of these species have been  found to cause disease 
in humans. In the United States, the majority of TB cases are caused by  M. 
tuberculosis. M. tuberculosis organisms are also called tubercle bacilli. 
(7)  
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 
1– 5 microns in diameter. Infectious droplet nuclei are generated when 
persons who have pulmonary or laryngeal TB disease cough, sneeze, shout, or 
sing. Depending on the environment, these tiny particles can remain 
suspended in the air for several hours. M. tuberculosis is transmitted through 
the air, not by surface contact. Transmission occurs when a person inhales 
droplet nuclei containing M. tuberculosis, and the droplet nuclei traverse the 
mouth or nasal passages, upper respiratory tract, and bronchi to reach the 
alveoli of the lungs. 
(8) 
TYPES OF TUBERCULOSIS 
 Active tuberculosis  
 Inactive tuberculosis 
 
Active tuberculosis 
Active tuberculosis means the bacteria are active in the body i.e., the 
immune system is unable to stop these bacteria from causing illness  
Inactive tuberculosis  
It is also known as latent TB. If a person has a latent TB, their body 
has been able to successfully fight against the bacteria and stop them from 
causing illness. People have latent TB do not feel sick, do not have symptoms 
and cannot spread tuberculosis. In the people who have HIV, the inactive TB 
may become active TB if their immune system becomes weakened. 
(9) 
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PATHOPHYSIOLOGY 
Humans are the only known reservoir for Mycobacterium tuberculosis. 
TB is transmitted by airborne droplet nuclei, which may contained fewer than 
10 bacilli. TB exposure occurs by sharing common airspace with an 
individual who is the infection stage of TB. 
Inhalation 
The bacteria are inhaled. The majority of the bacteria will become 
lodged in the upper respiratory tract , namely the nose and throat, where their 
survival is difficult. Some of the smaller particles, Hhough, will make it into 
the lungs and alveoli where infection sets in. Alternatively, the bacteria might 
be ingested.
(10) 
Bacteria multiplication 
In the alveoli, the bacteria are engulfed by inactivated macrophages, 
white blood cells present within tissues, where they multiply until the  
macrophage bursts. The Mycobacterium tuberculosis replicates very slowly, 
only once a every twenty four hours, and takes up to one month to form a 
colony. 
T-cell activation 
Dendritic cells are a key part of the mammalian immune system. When 
dendritic cells detect foreign substance entering the body, they engulf and 
bring them to the lymph nods where they present the antigens to certain white 
blood cells called T-cells. If the T-cell has a specific receptor for the 
presented antigen it will become activated to release potent molecules, such 
as interferon-gamma and tumour necrosis factor, which in turn stimulate 
macrophages and other T cells to produce a cell-mediated response against 
the bacteria carrying those antigens.     
Tubercle formation 
The T-cells return to the site of infection through the blood stream, 
where they   contribute to the formation of a tubercle or granuloma. The TB 
tubercle is made up of a core of infected macrophages, a surrounding ring of 
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foamy macrophages and an outside ring of T-cells, all enveloped in  fibrous 
shell. In some cases, an individual’s immune system is unable to defend 
against the bacteria by creating a tubercle to isolate it. Primary progressive 
tuberculosis occurs as a result. This is mostly seen in young children or 
individuals with much suppressed immune systems.  
When contained inside the granuloma the bacteria are inactive and the 
case of tuberculosis is considered to be latent. The bacteria are contained in 
the granuloma until the immune system is weakened, breaking down the outer 
ring of the tubercle, releasing the bacteria inside. In this situation, the case of 
tuberculosis has been reactivated and is known as secondary progressive 
tuberculosis. Only approximately 3-5% of immune-competent individuals will 
develop secondary progressive tuberculosis within two years of the primary 
infection, and a further 3-5% will develop it after two years.
(11) 
Cavitation and tubercle break-down 
In some cases, the damaged cells at the center of the granulation 
liquefy. The bacteria grow well in this liquid, multiplying outside of 
macrophages, their typical hosts. As they multiply, the tubercle enlarges. This 
can cause nearby tissue in the lungs to die and rupture, forming a cavity, or 
the tubercle to burst spreading bacteria further around the lungs or the body. 
This would also be considered a case of secondary progressive tuberculosis. 
The immune system will  responds  as per steps 3& 4 when the bacteria are 
recognized in their new locations.
(12) 
A small number of tubercle bacilli enter the bloodstream and spread 
throughout the body. The tubercle bacilli may reach any part of the body 
,including areas where TB disease is more likely to develop (such as the 
brains, larynx, lymph node, spine, bone, or kidney).
(13)
    
EPIDEMIOLOGY 
The highest incidences are seen in those countries of Africa, Asia, and 
latin America. The world health organization estimates that nine million 
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people get TB every year, of whom 95% live in developing countries. An 
estimated 2-3 million people die from TB every year. 
8.6 million people fell ill with in 2012, including 1.1 million cases 
among people living with HIV. In 2012, 1.3 million people died from TB, 
including 320 000 among people who were HIV positive. The mortality rate 
has decreased to 45% since 1990, and the 2015 global target of a 50% 
reduction in mortality is now within reach.
(14) 
Figure 2
(15) 
 
 
GENOME 
 Countless millions of people have died from Tuberculosis, a chronic 
infectious disease caused by the Tubercle Bacillus. The complete genome 
sequence of the best-characterized strain of Mycobacterium tuberculosis, 
H37Rv, has been determined and analyzed in order to improve our 
understanding of the biology of this slow-growing pathogen and to help the 
conception of new prophylactic and therapeutic interventions.
(16)
 The genome 
comprises 4,411,529 base pairs, Contains around 4,000 genes, and have a very 
high guanine + cytosine content that is reflected in the biased amino-acid 
content of the proteins. M. tuberculosis differs radically from other bacteria 
in that a very large portion of its coding capacity is devoted to the production 
of enzymes involved in lipo genesis and lipolysis, and to two new families of 
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glycine-rich proteins with a repetitive structure that may represent a source of 
antigenic variation.
(17) 
Figure 3 
(18)
  
 
 
LIFECYCLE OF MYCOBACTERIUM TUBERCULOSIS 
(19) 
There's 5 Stages of Tuberculosis  
1) Onset (1-7 Days): The Bacteria is inhaled. 
2) Symbiosis (7-21 Days): If the Bacteria do not get killed then it 
reproduces.  
3) Initial Caseous Necrosis (14-21 Days): Tuberculosis starts to develop 
when the Bacteria slow down at reproducing, they kill the surrounding 
non activated Macrophages and run out of cells to divide in. The 
Bacteria then produces anoxic conditions and reduces the PH. The 
Bacteria can't reproduce anymore but can live for a long time.  
4) 4. Interplay of Tissue Damaging and Macrophage Activating Immune 
Response (After 21 days): Macrophages surround the tubercle but some 
may be inactive. Tuberculosis then uses it to reproduce which causes it 
to grow. The tubercle can break off and spread around. If it spreads in 
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the blood one can develop tuberculosis outside the lungs, this is called 
Miliary Tuberculosis
5
.  
5) Liquification and Cavity Formation: The tubercles at one point will 
liquefy, which will make the disease spread faster, not everyone will 
get to this stage. Only a small percent of people will get to this stage.  
Figure 4
(20) 
 
CURRENT STATUS OF TUBERCULOSIS: 
Tuberculosis (TB) continues to remain one of the most pressing health 
problems in India. India is the highest TB burden country in the world, 
accounting for one fifth of the global incidence - an estimated 1.96million 
cases annually. Approximately 2.9million people die from tuberculosis each 
year worldwide; about one fifth of them in India alone .Nearly 500,000 die 
from the disease – more than1000 per day–one every minute.(21) The disease 
is a major barrier to social and economic development. An estimated 100 
million workdays are lost due to illness. The society and the country also 
incur huge cost due to TB–nearly US$ 3 billion in indirect cost and US$ 300 
million in direct costs. The situation is more complicated considering that 
disproportionately affects the young population in India. TB mortality in the 
country has reduced from an estimated 42 per lakh population in 1990 to 28 
per lakh population in 2006, and the prevalence of TB in the country has  
reduced from 568 per lakh population in 1990 to 253 per lakh population by 
the year 2014.
(22) 
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Figure 5
(23) 
 
 
MEDICAL CARE 
The tuberculosis vaccine, known as Bacilli Calmette-Gurine (BCG) 
may prevent the spread of tuberculosis and tuberculosis meningitis in 
children, but the vaccine does not necessarily protect against pulmonary 
tuberculosis. 
The chemotherapy of infectious disease, using sulfonamide and 
penicillins, had been underway for several years, but these molecules were 
ineffective against Mycobacterium tuberculosis. From 1943 streptomycin was 
used in treatment. Following streptomycin, p-aminosalicylic acid (1949), 
isoniazid (1952), pyrazinamide (1954), cycloserine (1955),ethambutol (1962), 
and rifampin, pyrazinamide, and ethambutal provide effective TB 
treatment.
(24) 
DIRECTLY OBSERVED THEARAPY 
For initial empiric treatment of tuberculosis (TB), start patients on a 4 -
drug regimen: Isoniazid, rifampin, pyrazinamide, and either ethambutol or 
streptomycin. Once the TB isolate is known to be fully susceptible, 
ethambutol (or streptomycin if used as a fourth drugs) can be discontinued.  
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After 2 months of therapy (for a fully susceptible isolate), 
pyrazinamide can be stopped. isoniazid plus rifampin are continued as daily 
or intermittent therapy for 4 more months. If isolated isoniazid resistance is 
documented, discontinue isoniazid and continue treatment with 
rifampin,pyrazinamide, and ethambutol for the entire 6 months. Therapy must 
be extentded if the patient has cavitary disease or remains culture-positive 
after 2 months of treatment.
(25) 
Directly observed therapy (DOT) is recommended for all patients. 
Patients on the above regimens as DOT can be switched to 2- to 3-times per 
week dosing after an intial 2 weeks of daily dosing. Patients on twice –weekly 
dosing must not miss any dose. Prescribe daily therpy for patients on self –
administered medication.
(26) 
DRUG RESISTANT OF TB 
TB organisms resistant to the antibiotics used in its treatment are 
widespread and occur in all countries. Drug resistance emerges as a result of 
inadequate treatment and once TB organisms acquire resistance they can 
spread from person to person in the same way as drug sensitive TB. 
MDR-TB 
Multidrug-resistance TB (MDR-TB) is caused by organisms that are 
resistant to the most effective anti-TB drugs (isoniazid and rifampicin). MDR-
TB results from either infection with organisms which are already drug-
resistance or may develop in the course of a patient’s treatment. (27) 
XDR-TB 
Extensively drug-resistance TB (XDR-TB) is a form is  TB caused by 
organisams that are resistant to isoniazid and rifampicin (i.e. MDR-TB) as 
well as any fluoroquinolone and any of the second-line anti-TB injectable 
drugs (amikacin,kanamycin or capreomycin). 
These forms of TB do not respond to the standard six month treatment 
with first-line anti-TB drugs and can take two years or more to treat with 
drugs that are less potent, more toxic and much more expensive.
(28) 
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THE NEED FOR NOVEL TUBERCULOSIS DRUGS 
 To improve the treatment of MDR-TB. 
 To provide more effective treatment of latent tuberculosis infection.  
 XDR TB disease is resistant to first-line and second-line drugs, 
patients are left with treatment  options that are more toxic, more 
expensive, and much less effective. 
 Discovery of a compound that would reduce both the total duration of 
treatment and the frequency of drug administration.  
 With multidrug resistant cases of tuberculosis increasing globally, 
better antibiotic drugs and novel drug targets are becoming an urgent 
need.
(28)
 
ENZYME  
TARGET  : L, D-TRANSPEPTIDASE-2 
 Traditional β-lactam antibiotics that inhibit D,D-transpeptidases are 
not effective against mycobacteria, because mycobacteria rely mostly 
on L,D-trans peptidases for biosynthesis and maintenance of their 
peptidoglycan layer. 
 This reliance plays a major role in drug resistance and persistence of 
Mycobacterium tuberculosis (Mtb) infections. 
 The crystal structure at 1.7 Å resolution of the Mtb L,D-transpeptidase 
containing a bound peptidoglycan fragment, provides information 
about catalytic site organization as well as substrate recognition by the 
enzyme. 
 Based on structural, kinetics, and calorimetric data, a catalytic 
mechanism for LdtMt2 in which both acyl- acceptor and acyl-doner 
substrates reach the catalytic site from the same, rather than 
different,entrance has been proposed by Sabri B. Erdemli et al.  
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 This information provides vital insights that facilitate development of 
drugs targeting this validated yet unexploited enzyme.
(29)
 
Figure 6
(29)
 
 
BASIC NUCLEUS INTRODUCTION 
HETEROCYCLIC CHEMISTRY: 
Heterocyclic structures always are a part in the field of research and 
development in organic chemistry. Millions of heterocyclic structures are 
found to exist having special properties and biological importance. Among 
various compounds, we have chosen imidazole, a fused diazole heterocyclic 
structure. This ring system is present in important biological building- blocks, 
such as histidine, and the related hormone histamine. Many drugs contain an 
imidazole ring.
(30) 
IMIDAZOLE NUCLEUS:  
Imidazole is a planar five-member heterocyclic ring with 3C and 2N 
atom and in ring N is present in 1st and 3rd positions. The imidazole ring is a 
constituent of several important natural products, including purine, histamine, 
histidine and nucleic acid. Imidazole derivatives have occupied a unique place 
in the field of medicinal chemistry. The incorporation of the imidazole 
nucleus is an important synthetic strategy in drug discovery.
(31)
 The high 
therapeutic properties of the imidazole related drugs have encouraged the 
medicinal chemists to synthesize a large number of novel chemotherapeutic 
agents.
(32) 
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BENZIMIDAZOLE  
NUCLEUS 
Benzimidazole is a heterocyclic aromatic organic compound. This 
bicyclic compound consists of the fusion of benzene and imidazole. The most 
prominent benzimidazole compound nature is N-ribosyl-
dimethylbenzimidazole, which serves as an axial ligand for cobalt in vitamin 
B12.
(33)
  
Benzimidazole also has fungicidal properties. It acts by binding to the 
fungal microtubules and stopping hyphal growth. It also binds to the spindle 
microtubules and blocks nuclear division.
(34) 
 
On the basis of various literature surveys Imidazole and Benzimidazole 
derivatives shows various pharmacological activities.
(35)
,
(36)
  
 Anti-tubercular activity. (37) 
 Anti-fungal and Anti-bacterial activity.  
 Anti-inflammatory activity and analgesic activity.  
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 Anti-depressant activity.  
 Anti-cancer activity. (38) 
 Anti-viral activity.  
 Antileishmanial activity.  
On view of the importance of the imidazole and benzimidazole 
nucleus. It was decided to design molecule based on the imidazole and 
benzimidazole nucleus. 
DRUG DISCOVARY,DESIGN AND DEVELOPMENT 
DRUG DISCOVERY 
The process of drug discovery is very complex and requires  
interdisciplinary effort to design effective and commercially feasible drugs. 
Earlier drug discovery was a trial and error process. The process of drug 
development has evolved with time. New understanding of the quantitative 
relationship between structure and biological activity ushered the beginning 
of computer-aided drug design.
(39)
 With the help of computers, a new era has 
begun in drug discovery. The development cost will be cut by almost a third. 
The development times are reduced. 
LEAD AND LEAD OPTIMIZATION 
A Lead is defined as a compound, usually a small organic molecule 
that Demonstrated desired biological activity on a validated molecular target. 
Lead optimization is a technique of refining 3D structures of drug molecules 
and promoting the binding of drug to protein active sites. In this technique the 
modification of the structure of the drug molecules is done by docking every 
specific structure of a drug compound in active site of protein and calculating 
the extent of their interactions.
(40)
 Optimization aids in the structural 
modification of newer molecules in order to improve the physico-chemical 
properties and biological activity for a given set of compounds in the 
library.
(39)
Further structural modification improves the affinity, reactivity 
towards target and enhances stability during metabolism.  
Computer aided drug design
(41) 
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Computer aided drug design uses computational chemistry to discover, 
enhance or study drugs and related biologically active molecules. The most 
fundamental goal is to predict whether a given molecule will bind to a target 
and if so how strongly. Molecular mechanics or molecular dynamics are most 
often used to predict the conformation of the small molecule and to model 
conformational changes in the biological target that may occur when the small 
molecule binds to it. This provides semi-quantitative prediction of the binding 
affinity. Also, knowledge-based scoring function may be used to provide 
binding affinity estimates. These methods use linear regression, machine 
learning, neural nets or other statistical techniques to derive predictive 
binding affinity equations by fitting experimental affinities to 
computationally derived interaction energies between the small molecule and 
the target.
(42) 
Rational drug design
(43) 
Drug design is a process which involves the identification of a 
compound that displays a biological profile and chemical synthesis of the new 
chemical entity are optimized. Drug designing is otherwise known as rational 
drug design and it is a method of finding new medications, based on the 
biological receptors and target molecules. The objective  of drug design is to 
find a chemical compound that can fit to a specific cavity on a protein target 
both geometrically and chemically.  
Figure 7
(44) 
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Types of drug design 
 Ligand based drug design 
 Structure based drug design 
Ligand based drug design 
Ligand based drug design is an indirect approach which relies on 
knowledge of other molecules that bind to the biological target of interest. 
These other molecules may be used to derive a pharmacophore model that 
defines the minimum necessary structural characteristics a molecule must 
possess in order to bind to the target. In other words, a model of the 
biological target may be built based on the knowledge of what binds to it, and 
this model in turn may be used to design new molecular entities that interact 
with the target. 
 Structure based drug design
 
Structure based drug design is a direct approach which relies on 
knowledge of the three dimensional structure of the biological target obtained 
through methods such as x-ray crystallography and NMR spectroscopy.  If an 
experimental structure of a target is not available, it may be possible to create 
a homology model of the target based on the experimental structure of a 
related protein. Using the structure of the biological target, candidate drugs 
that are predicted to bind with high affinity and selectivity to the target may 
be designed using interactive and selectivity to the target may be designed 
using interactive graphics and the intuition of a medicinal chemist or various 
automated computational procedures to suggest new drug candidates.
(45) 
Docking
 
Docking is simply refer to the ability to position a ligand in the active 
or a designated site of a protein and calculates the specific binding affinities. 
Ligand-protein docking as evolved so remarkably throughout the past decade 
that docking single or multiple small molecules to a receptor site is now 
routinely used to identify ligands. Optimal docking procedures need to be 
fast, generate reliable ligand geometries, rank the ligand conformation 
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correctly (scoring) and thereby, estimate the binding energy. A number of 
studies have shown that docking algorithms are capable of finding ligands and 
binding conformations at a receptor site close to experimentally determined 
structures. These algorithms are equally applicable to the identification of 
multiple proteins to which a small molecule can bind. The application of this 
approach may facilitate the prediction of either unknown and secondary 
therapeutic target proteins their side effects and toxicity of particular drugs . 
In computational structure-based drug design, the evaluations of scoring 
functions are the cornerstones to the success of design and discovery. Many 
approaches have been explored to improve their reliability and accuracy, 
leading to three families of scoring functions. These are force-field-based, 
knowledge-based, emprical-based.
(46) 
Scoring function
 
Scoring functions are normally parameterized (or trained) against a 
data set consisting of experimentally determined binding affinities between 
molecular species similar to the species that one wishes to predict.  
Types 
1) Force field based - Force-field affinities are estimated by summing the 
strength of intermolecular vanderwaals and electrostatic interactions 
between all atoms of the two molecules in the complex. 
2) Emprical - Based on coming the number of various types of 
interactions between the binding partners. Counting may be based on 
the number of ligand and receptor atoms in contact with each other or 
by calculating the change in solvent accessible surface area complex 
compared to the uncomplexed ligand and protein. These interaction 
terms of the function may include for example: hydrophobic-
hydrophobic contacts, hydrophobic-hydrophilic contacts, number of 
hydrogen bonds, number of rotatable bonds immobilized in complex 
formation. 
Introduction 
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3) Knowledge-based (also known as statistical-potentials) - Based on 
statistical observations of intermolecular close contacts in large 3D 
databases which are used to derive "potentials of mean force". This 
method is founded on the assumption that close intermolecular 
interactions between certain types of atoms or functional groups that 
occur more frequently than one would expect by a random distribution 
are likely to be energetically favourable and therefore contribute 
favourably to binding affinity.
(47) 
Absorption, Distribution, Metabolism and Excretion (ADME) 
analysis  For a drug to be pharmacologically active and exert the action it 
should possess appropriate pharmacokinetic properties like Absorption, 
Distribution, Metabolism and Excretion. In the field of drug research and 
development many drug failures do occur, such that the drug may fail to 
undergo those properties satisfactorily.  
This has to be ruled out earlier in the process of drug discovery. Many 
In vitro studies are more frequently used to evaluate ADME properties. Some 
computational methods (In silico tools) have been evolved to investigate the 
most suitable drug molecules.  
In silico modeling serves for two main functions in predicting those 
(ADME) properties i.e, 
 Earlier investigation of designing compounds and compound libraries 
in order to reduce the risks at later.  
 Optimizes the screening and testing, most probably by focusing only 
on the more active compounds. 
 A deep rooted knowledge in understanding the relationship of ADME 
parameters and the underlying (drug likeness property) molecular 
structural features to which it depends on.  
 It enhances in elaborating this session of interest to the area of 
posology where it gives information about the drug dosage and 
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frequency. This in turn reflects on issues on bioavailability, crossing 
various biological membranes like brain, ocular and dermal 
penetration. 
These are the essential factors and criteria to look in, for a drug to be 
pharmacologically active and execute as the most successful clinical 
candidate in the pharmaceutical research.  
Prediction of ADME related parameters 
Absorption 
To investigate this property in in silico model used simple parameters 
like log D (diffusion coefficient) and polar surface area are the descripto rs for 
hydrogen bonding capacity and log P (partition coefficient) values should fall 
under the prescribed values asper the rule of thumb which determines the 
absorption. 
Bioavailability 
Factors like size and shape of molecule, lipophilicity and flexibilit y 
determines the bioavailability. 
Blood Brain Barrier Penetration 
In order for a drug to cross the blood brain barrier (molecule targeted 
to brain). Rule of thumb says log P values should be closer to 2 with a 
molecular mass of <450 Da and or with a polar surface area (PSA) <100 A are 
likely to possess. 
Dermal and Ocular Penetration 
For dermal and ocular route it should satisfy the existing parameters 
like log P (partition coefficient) for aqueous solubility, molecular weight and 
molecular flexibility. 
Metabolism
 
Various in silico approaches exist in evaluating the metabolism namely 
QSAR and 3D QSAR etc. apart from those computational chemists have 
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updated the structural details in the data bases and tools for predicting 
metabolism. Simultaneously it reveals the metabolic information as well as 
the toxicity related to the molecular fragments by which the drug molecule 
undergoes the metabolism.
(48) 
Evaluation of in silico toxicity
 
Toxicity is one of the major criteria to be considered for a molecule to 
shine as a successful clinical candidate in the pharmaceutical research. About 
~20-40% of the drug failures, fall under this category. Commercial in silico 
tools estimates toxicity and provides information by the use of QSAR 
(parameters and descriptors), scientific literatures and to some extent in 
abstracting issues from humans. 
In silico approaches like OSIRIS
®
 property explorer predicts 
carcinogenicity, mutagenicity, teratogenicity, immune toxicology, irritation, 
sensitization etc. In addition, hepato, neuro and cardiotoxicity are evaluated 
in newly updated in silico tools. 
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AIM AND PLAN OF WORKS 
Objective of the Present Study 
AIM 
The aim of this project is to develop potential antimycobacterial 
agents. 
OBJECTIVES 
The objective of the project is to design and synthesize some 
compounds which will act on L,D Transpeptidase 2 and inhibit the cell wall 
synthesis of M.tuberculosis. 
THE PLAN OF WORK 
 Design of L,D Transpeptidase 2 inhibitors by docking studies  
 Insilico Prediction of Drug Likeness and Toxicity 
 Laboratory synthesis of the top G score compounds 
 Characterization of the synthesized compounds by  
o Infrared Spectrometry  
o Nuclear Magnetic Resonance Spectroscopy  
o Mass Spectrometry 
 Determination of In-vitro anti tubercular activity of synthesized 
compounds. 
The whole study was carried out according to the flow chart.  
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The present study carried out based on the below flow 
Identification of the lead compound 
 
Lead optimization 
 
Docking of the molecule to the target protein 
 
Top G score compounds selected 
 
Insilico drug likeness  and toxicity risk assessment  
 
Synthesis 
 
Justification of purity-TLC, GC 
 
Characterization – Spectroscopy (IR,NMR,GC- MS,LC-MS) 
 
Invitro anti-tubercular activity 
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REVIEW OF LITERATURE 
The Review of Literature related to the  genomic  of the 
Mycobacterium Tuberculosis:  
1) Rahul Jain et al.,(2005) Tuberculosis (TB) is one of the most 
devastating diseases primarily due to several decades of neglect, and 
presents a global health threat of escalating proportions. TB is the 
second leading infectious causes of mortality today behind only 
HIV/AIDS. (49) 
2) James C. Sacchettini et al., (2004) worked on TB drug discovery. 
Addressing issues of persistence and resistance by reviewing the recent 
developments of some of the pathways involved in a persistent 
infection and pathogenesis of mycobacterium tuberculosis, which 
reveal new targets for drug development. (50) 
The Review of Literature related to the  target enzyme, 4GSU and its 
function: 
3) Kim et al.,(2013) worked on Structure basis for the inhibition of 
Mycobacterium tuberculosis L, D-transpeptidase by meropenem, a drug 
effective against extensively drug-resistant strain.
(51) 
4) Hyoun Sook Kim., et al.(2012) reported on structure basis for the 
inhibition of Mycobacterium Tuberculosis L,D-transpeptidase by 
meropenem, a drug effective against
(52) 
The Review  related to  the drug design study:  
5) Deepak. D. Borkar., et al. (2012), Design and Synthesis of p-hydroxy 
benzohydrazide Derivatives for their Antimycobacterial Activity. (53) 
6) Romono T. Kroemeret et al.(2003), An introduction into ligand–
receptor docking. It illustrates the basic underlying concepts. (54)  
7) Andrew Worth et al.(1998), Distribution, Metabolism and Excretion 
(ADME) properties, which are often important in discriminating 
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between the toxicological profiles of parent compounds and their 
metabolites/degradation products. (55) 
8) Lipinski CA et al., (2001) A experimental and computational 
approaches to estimate solubility and permeability in drug discovery 
and development settings. (56)  
9) Lipinski CA (2004) A Lead and drug-like compounds and the role of 
fine resolution. (57)  
10) Madsen et al., (2002) Textbook of Drug Design and Discovery. (54) The 
review on following works provided ideas for synthesis of the desired 
chemical entities: 
The Review of Literature related to the desired chemical entities:  
11) Debus et al.(1858), Debus Synthesis of imidazole by using glyoxal and 
formaldehyde in ammonia. This synthesis, while producing relatively 
low yields, is still used for creating C substituted Imidazoles. (58) 
 
12) Radiszewski et al. Radiszewski reported the condensation of a 
dicarbonyl compound, benzil and α- keto aldehyde or benzaldehyde in 
the presence of ammonia, to yield 2, 4, 5 triphenylimidazole. (59) 
 
13) Qasim et al (2011) Synthesis of  2- phenylimidazo [4,5-f] [1,10] 
Phenanthroline derivatives, by reacting dicarbonyl compound and p-
substituted benzaldehyde. This is a type of acid catalyzed reaction with 
excellent yields in a neutral ionic liquid, 1-methyl-3-
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heptylimidazolium tetrafluoroborate [(HeMIM) BF4], under solvent 
free and microwave assisted conditions. This particular reaction 
accompanies all the merits of microwave reactions like easy workup, 
better yield, and environment friendly reaction. 
(60) 
 
14) Na Zhao et al (2005) Reported an efficient and a quick microwave-
assisted synthesis of  benzimidazoles and trisubstituted imidazoles. 
(61) 
 
 
15) Pathan et al (2006) Reported the reaction of alkyl cyanide with 
ethylenediamine in the presence of carbon disulphide gives 2-
substituted 2 imidazolines under microwave irradiation. 
(62) 
 
16) Ermolat et al (2009) Explained the synthesis of mono and 
disubstituted-2-amino-1H imidazoles Via microwave assisted 
hydrazinolysis of substituted imidazo[1,2a]pyrimidines.
(63)
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17) Raghavendra et al (2011) A Series of 1-(2-((18Z)-4-substituted 
benzylidene-4, 5-dihydro-5- oxo-2-phenylimidazol-1-yl) ethyl)-1, 2-
dihydro-4-methyl-2-oxoquinolin-7-yl  imidazole quinoline analogs is 
synthesized by condensation of substituted imidazole and substituted 
quinolone. 
(64) 
 
 
18) Safari et al (2010) (NH4)6.Mo.7O2. 4H2O was used as an efficient 
catalyst for an improved and rapid synthesis of 2,4,5-trisubstituted 
imidazoles by a three-component, one-pot condensation of benzil, aryl 
aldehydes and ammonium acetate in good yields under solvent -free 
conditions using microwave irradiation. The reactions in conventional 
heating conditions were compared with the microwave-assisted 
reactions. 
(60) 
 
19) Nalage et al (2010) Described an efficient and green procedure for the 
synthesis of 2, 4, 6-triaryl- 1H-imidazole in polyethylene glycol by 
condensing benzil and 3-methoxy- 4- hydroxyl benzaldehyde under 
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microwave irradiation in excellent yield. Polyethylene glycol is non-
toxic, reusable, inexpensive and easily available. 
(65) 
 
20) Wahyuningrum et al (2007)  Explained 4,5-substituted imidazole 
derivatives have been synthesized utilizing microwave assisted 
organic synthesis (MAOS) method, by reacting with suitable diketone 
and some aldehyde or ketone, in order to investigate their corrosion 
inhibition mechanism on carbon steel surface. 
(66) 
 
21) Kawashita et al (2009), A variety of hetero aromatic compounds such 
as 2-substituted imidazoles were synthesized by oxidative 
aromatization of 2-substituted imidazolines using the activated carbon 
and molecular oxygen system. 
(67) 
 
22) Sparks et al (2004)  Synthesis of 2,4,5-Triaryl-imidazoles directly 
from the ketooxime in moderate to good yields via cyclization to the 
N-hydroxyimidazole and an unprecedented in situ thermal reduction of 
the N-O bond upon microwave irradiation at 200  C for 20 min. (68) 
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23.Satyajit et al (2010) A series of 2-substituted-4,5-diphenyl 
imidazoles were synthesized by refluxing benzil with different sub-stituted 
aldehydes in the presence of ammonium acetate and glacial acetic acid. 
Compounds were screened for anthelmintic activity. 
(69) 
 
Review of Literature related to the target: L,D-Transpeptidase 
23) Wen-Juan Li et al.,(70)Crystal structure of L,D-transpeptidase LdtMt2 
in complex with meropenem reveals the mechanism of carbapenem 
against Mycobacterium tuberculosis. 
24) Sabari b. erdemli et al,(71) studied that the traditional β-lactam 
antibiotics that disrupt the D,D-transpeptidases are not effective 
against mycobacteria. As mycobacteria rely mostly on β-lactam 
insensitive L,D-transpeptidases for biosynthesis and maintenance of 
their peptidoglycan layer. Based on the structural, kinetic and 
calorimetric data, catalytic mechanism for LdtMtb2 has been proposed.  
25) Lauriane Lecoq et al,(72) Dynamics Induced by β-Lactam Antibiotics 
in the Active Site of Bacillus subtilis L,D-Transpeptidase . 
26) Soumya De and Lawrence P. McIntosh (73) investigated the structural 
and dynamic basis for the unexpected inhibition of peptidoglycan 
crosslinking L,D-transpeptidases by carbapenam antibiotics.  
27) Dominic Both et al,(74) studied the crystal structure of the protein and 
summarized that he transpeptidase LdtMt2 catalyzes the formation of 
the cross links characteristics of the peptidoglycan layer in the 
Mycobacterium tuberculosis cell wall.  
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Review of Literature related to the evaluation of anti tubercular activity by 
MABA 
28) Scott G. Franzblau et al,(75) studied MIC determination by MABA. A 
colorimetric, Microplate Based Alamar Blue Assay (MABA) method 
was used to determine the MICs of Isoniazid, Rifampin, Streptomycin 
and Etambutol for 34 peruvian Mycobacterium tuberculosis isolates 
and the H37Rv strain by using bacterial suspensions prepared directly 
from media. The MABA is a simpe, rapid, low cost, appropriate 
technology which does not require extensive instrumentation and 
which makes use of a nontoxic, temperature stable reagent . 
29) Sephra N. Rampresad et al, (76) studied the various applications of 
Alamar Blue as an indicator. Alamar Blue is a redox indicator that is 
used to evaluate metabolic function and cellular health. The Alamar 
Blue Bioassay is being utilized to access cell viability and cytotoxicity 
in a range of biological and environmental system and in a number of 
cell types including bacteria, yeast, fungi, and protozoa.  
30) Jose de Jesus Alba-Romero et al,(77) applied the Alamar Blue Assay 
to determine the susceptibility to anti-tuberculosis pharmaceuticals. 
The result showed that the MABA test is fast and easy to apply. It is a 
very reliable method of determining the drug susceptibility to 
pharmaceuticals. 
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MATERIALS AND METHODS 
DRUG DESIGN  
Docking program is used to fit the ligand molecules into the target 
structure in a variety of positions, confirmations, and orientations. Docking 
mode is known as pose. Each pose is scored, based on its complementarity to  
the target in terms of shape and electrostatic properties. This is done to 
identify the most favorable energetical pose.  
The quality of any docking result depends on the starting structure of 
both the protein and the potential ligand. The protein and ligand structures 
need to be prepared to achieve the best docking results.
(78)
 
MOLECULAR DOCKING BY DRUG DESIGN 
Argus lab 4.0 is distributed freely for windows platforms by planaria 
software. It is an introductory molecular modeling package for academics. 
Argus docking engine implement in Argus lab approximates an exhaustive 
search method which is similar to DOCK
®
 and GLIDE
®
. Flexible ligand 
docking is possible with Argus lab, where the ligand is described as torsion 
tree and grids are constructed that overlay the binding site. The accuracy of 
the Argus lab docking algorithm takes into account, the key features such as 
the nature of the binding site and the number of rotatable bonds in the 
ligand.
[79] 
Protein Preperation
 
 The crystallized structure of the receptor/protein is imported from 
Protein DataBank (PDB). The PDB id: 4GSU it refers to the target L,D 
Transpeptidase 2. The PDB  file was selected based on its species, X-ray 
crystallography or NMR spectroscopy, resolution value 2.8 A, external ligand 
and presence of co-factor.
(80)
.The water  molecules, co-factor and unwanted 
chains were deleted. And the energy minimization has been done so that it 
will  be ready for grid generation. 
 
Materials & Methods 
College of Pharmacy, MMC, Chennai-3. Page No.30 
Figure 8 
(81) 
 
TYPES OF DRUG DESIGN: 
(82)
  
 Ligand based drug design. 
 Structure based drug design. 
Ligand Based Drug Design  
Ligand based drug design is an approach used in the absence of the 
receptor 3D information and it relies on knowledge of molecules that bind to 
the biological target of interest. 3D quantitative structure activity 
relationships (3D QSAR) and Pharmacophore modeling are the most 
important and widely used tools in ligand based drug design. They can 
provide predictive models suitable for lead identification and optimization.  
De Novo Drug Design  
De novo is a Latin expression meaning "from the beginning". Active 
site of drug targets when characterized from a structural point of view will 
shed light on its binding features. This information of active site composition 
and the orientation of various amino acids at the binding site can be used to 
design ligands specific to that particular target. Computational tools that can 
analyze protein active site and suggest potential compounds are extensively 
used for de novo design methods.  
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Structure Based Drug Design(SBDD)  
If  the approach where the structural information of the drug target is 
exploited for the development of its inhibitor. Receptor structure(s) is a 
prerequisite for this method. Most commonly the structure of the receptor is 
determined by experimental techniques such as X-ray crystallography or 
NMR. If the structure of the protein drug target is not available, protein 
structure can be predicted by computational methods like threading and 
homology modeling. Threading (also called as fold) is a modeling approach 
used to model proteins that do not have homologous proteins with known 
structure.
(83)
  
DOCKING  
Docking involves the fitting of a molecule into the target structure in a 
variety of positions, conformations and orientations. Molecular docking is 
used to predict the structure of the intermolecular complex formed between 
two molecules.
(84)
 The small molecule called ligand usually interacts with the 
protein binding site.There are several possible mutual conformations in which 
binding may occur. These are commonly called binding modes. It also 
predicts the strength of the binding, the energy of the complex; the types of 
the complex; the types of the signal produced and calculates the binding 
affinity between two molecules using scoring functions. The most interes ting 
case is the type protein-ligand interaction, which has its applications in 
medicine.
(85) 
TYPES OF DOCKING  
 Lock And Key or Rigid Docking (84) - In rigid docking, both the 
internal geometry of the receptor and ligand is kept fixed and docking 
is performed.  
 Induced Fit or Flexible Docking (84) - an enumeration on the rotations 
of one of the molecules (usually smaller one) is performed. Every 
rotation the surface cell occupancy and energy is calculated; later the 
most optimum pose is selected.  
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STEPS INVOLVED IN DOCKING 
(86)
,
(87)
,
(88)
    
Docking is done by using ARGUS LAB Software.  
1) Protein preparation. 
2) Selection of active site (Q-Site finder). 
3) Ligand Preparation. 
4) Docking Procedure.  
5) Visualization / Interpretation of Docking.  
PROTEIN PREPARATION  
 Step:1  
 The PDB id(4GSU) is entered in the protein data bank.    
 The pdb files are downloaded and text file  selected.  
 The downloaded pdb (text file)is saved in the desktop.   
 Step: 2 
 In the Argus lab software, the pdb file is imported from the 
desktop and the 3D structure of the protein appears in the 
workspace of Argus lab. 
 The molecular tree view will appear on left side of screen and 
the pdb is opened and residues ,miscellaneous are viewed.  
 Miscellaneous option is selected and the inhibitor and hetero 
residues and water molecules deleted.  
 The hydrogen atoms are added  
 The energy is selected on the calculation toolbar by UFF method 
and started.  
 The prepared protein is saved as *.agi file format in the desktop.  
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Q-SITE FINDER  
 Q-site finder is an energy-based method for protein-ligand binding site 
prediction. During prediction we use the crystal structures of 
macromolecules (receptor) with small substrates (pdb ID).  
 Identifying the location of binding sites on a protein is of fundamental 
importance for a range of applications including molecular docking. It 
uses the interaction energy between the protein and a simple 
vanderwaals probe to locate energetically favourable binding sites.  
LIGAND PREPARATION  
 The structure is drawn from Chem sketch and save as MDL Mol 
format. The ligand is imported into the  workspace of Argus lab.  
 The Geometry and  Hybridisation is cleaned.  
 Identify the location of  ligand and  make a group from the residues 
and name as ligand.  
DOCKING PROCEDURE 
 Then set up a Dock Ligand calculation which is selected from the 
toolbar.  
 Argus Dock is selected from  Docking Engine.  
 Dock is selected as calculation type.  
 Flexible is selected from the scoring function. 
 The docking is started and docked protein ligand complex is saved as 
Brookhaven pdb files (*pdb) 
VISUALIZATION / INTERPRETATION OF DOCKING 
 Molegro Molecular viewer 
 Molegro molecular viewer is an application which helps in analyzing 
the energies and interaction of the binding site.  
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 Secondary structure and hydrogen bond interaction,ligand map interaction 
is viewed.  
MOLECULAR PROPERTY PREDICTION: (89) 
All the docked molecules are subjected to the toxicity risk assessment 
by using OSIRIS
®
program, which is available online. The OSIRIS
®
 property 
Explorer an integral part of Actelion's in house substance registration system. 
It allows drawing chemical structures and also calculates various drug 
relevant properties whenever a structure is valid. Prediction results are color 
coded in which the red colour shows high risks with undesired effects like 
mutagenicity or a poor intestinal absorption and green colour indicates drug-
conform behavior. Molecular property prediction includes  
 Toxicity risk assessment.  
 clogP predicition.  
 Solubility prediction.  
 Molecular weight.  
 Drug likeness prediction.  
 Drug likeness score. 
TOXICITY RISK ASSESSMENT  
On drawing a structure the toxicity risk predictor will start looking for 
potential toxicity risks as long as the structure is a valid chemical entity. 
Toxicity risk alerts are an indication that the drawn structure  may be harmful 
concerning the risk category specified. The prediction process relies on a 
precomputed set of structural fragment that give rise to toxicity alerts in case 
they are encountered in the structure currently drawn. These fragment lists 
were created by rigorously shreddering all compounds of the Registry of 
Toxic Effects of Chemical Substance (RTECS) database known to be active in 
a certain toxicity class like mutagenicity, Tumorigenicity, Irritating effects 
and Reproductive effects. (89) 
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clogP PREDICTION 
The logP value of a compound, which is the logarithm of its partition 
coefficient between n-octanol and water log(coctanol/cwater), is a well 
established measure of the compound's hydrophilicity. Low hydrophilicities 
and therefore high logP values cause poor absorption or permeation. clogP 
value must not be greater than 5.0 for permeability.  
SOLUBILITY PREDICTION  
The aqueous solubility of a compound significantly affects its 
absorption and distribution characteristics. Typically, a low solubility  goes 
along with a bad absorption and therefore the general aim is to avoid poorly 
soluble compounds.  
MOLECULAR WEIGHT 
Optimizing compounds for high activity on a biological target almost 
often goes along with increased molecular weights. However, compounds 
with higher weights are less likely to be absorbed and therefore to ever reach 
the place of action. Thus, trying to keep molecular weights as low as possible 
should be the desire of every drug forger.  
DRUG LIKENESS  
Druglikeness is a qualitative concept used in drug design for how 
"druglike" a substance is with respect to factors like bioavailability. It is 
estimated from the molecular structure before the substance is even 
synthesized and tested. A druglike molecule has properties such as:Solubility 
in both water and fat, as an orally administered drug needs to pass through the 
intestinal lining after it is consumed, carried in aqueous blood and penetrate 
the lipid cellular membrane to reach the inside of a cell. A model compound 
for the lipophilic cellular membrane is octanol (a lipophilic hydrocarbon), so 
the logarithm of the octanol/water partition coefficient, known as LogP, is 
used to predict the solubility of a potential oral drug. This coefficient can be 
experimentally measured or predicted computationally, in which case it is 
sometimes called "cLogP". 
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LIPINSKI’S RULE OF FIVE (90), (91) 
Lipinski's rule of five also known as the Pfizer's rule of five or 
simply the Rule of five (RO5) is to evaluate druglikeness or d etermine if a 
chemical compound with a certain pharmacological or biological activity has 
properties that would make it a likely orally active drug in humans. The rule 
was formulated by Christopher A.Lipinski in 1997. The rule describes 
molecular properties important for a drug’s pharmacokinetics in the human 
body, including their absorption, distribution, metabolism, and excretion 
("ADME"). However, the rule does not predict if a compound is 
pharmacologically active. Lipinski's rule states that, in general, an orally 
active drug has no more than one violation of the following criteria:  
Figure9
(91) 
 
 
SYNTHETIC INVESTIGATION  
Scheme-1 
A Mixture of 1 mole of Phenanthrene 9,10-dione, 1 mole of Substituted 
aromatic aldehyde and 2 mole of Ammonium acetate is taken in a round 
bottom flask with  Poly ethylene glycol which  acts as a catalyst and the 
mixture is refluxed. On completion of reaction as monitored by TLC at an 
interval of 30 minutes. The sticky mass is transferred to acetone: water (6:4) 
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mixture. The  precipitate that is obtained is filtered, dried and recrystallized. 
It is finally purified by using column choromatography. (92) 
OO
+
CHO
+ NH4OAc
NHN
PEG
Phenanthrene 9,10 Quinone Benzaldehyde derivatives Ammonium acetate
Imidazole derivative
R1
 
Scheme-2 
A mixture of 1 mole of Benzil, 1 mole of Substituted aromatic 
aldehyde and 2 moles of Ammonium acetate is taken in a round bottom flask 
with  Poly ethylene glycol which  acts as a catalyst and the mixture is 
refluxed. On completion of reaction, as monitored by TLC at an interval of 30 
minutes. The sticky mass is transferred to acetone: water (6:4) mixture. The  
precipitate which is obtained is filtered, dried and recrystallized. It is finally 
purified by using column choromatography. (93) 
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OO
+
CHO
+ NH4OAc
NHN
PEG
Benzaldehyde derivatives Ammonium acetate
Imidazole derivative
R1
1,2-diphenylethane-1,2-dione
 
Reactant profile 
 
Benzil Phenanthrene 9,10-dione 
  
OO
 
NHN
OH
 
Molecular formula : C14H10O Molecular formula : C14H8O2 
Moleculae weight : 208.21g/mol Moleculae weight : 210.22g/mol. 
Discription : Orange red crystals Discription : Yellow Crystals 
Melting point : 209-212  C Melting point : 94-96
0
C 
Boiling point : 360  C Boiling point : 348
0
C 
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Furaldehyde 
OOHC
 
Molecular formula : C5H4O2 
Moleculae weight : 96.08g/mol. 
Discription  : Reddish brown oily liquid 
Melting point : -37
0
C 
Boiling point  : 162
0
C 
 
 
2,3 difluro-6-methb oxy benzaldehyde 
F
F
H3CO
CHO
 
Molecular formula : C8H6F2O2 
Moleculae weight : 172.12g/mol.  
Discription  : white colour powder 
Melting point : 55
0
C 
Boiling point  : 233.5  C 
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Vanillin 
OH
OCH3
CHO  
Molecular formula : C8H8O3 
 Moleculae weight : 152.14g/mol.  
 Discription  : white crystalls 
 Melting point : 81oC 
 Boiling point : 285.5  C 
 
Thiophene 2 carboxyaldehyde  
S
O
 
Molecular formula : C5H4OS 
Moleculae weight : 112.15g/mol. 
Discription           : brown colour liquid 
Melting point : 78
0 
C
 
Boiling point  : 196.5
0
C 
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4-Dimethylaminobenzaldehyde 
N
CH3CH3
CHO  
Molecular formula : C9H11NO 
Moleculae weight : 149.18g/mol. 
Discription  : Crystalline powder 
Melting point : 74 
0
c 
Boiling point : 176-177 c 
 
 
4-Pyridine carboxyaldehyde 
N
CHO
 
Molecular formula : C5H5NO 
Moleculae weight : 107.11g/mol. 
Discription  : yellow to brown  liquid. 
Melting point : -4 to 2 
Boiling point  : 198 
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Pyrrole 2 Carboxyaldehyde 
N
H
CHO
 
Molecular formula : C5H5NO 
Moleculae weight : 95.0g/mol.  
Discription  : Pale yellow crystalline solid 
Melting point : 48 c  
Boiling point  : 218 c 
                                                                                 
2-Chloro 5- Nitro Benzaldehyde 
Cl
O2N
 
Molecular formula : C6H4 CLNO2 
Moleculae weight : 157.55g/mol. 
Discription  : Clear slightly yellow powder 
Melting point : 75-77 c 
Boiling point  : 290.3 c 
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CHARACTERIZATION PHYSICAL EVALUATION:  
Physical properties of the synthesized compounds are evaluated,such as  
1) Colour  
2) Nature  
3) Solubility  
4) Molecular weight  
5) Molecular formula  
6) Melting point  
7) Boiling point 
THIN LAYER CHROMATOGRAPHY
 
The precoated  aluminum TLC-GF binder was used. Solution of the 
reactants and products in ethanol are prepared. Various mobile phases  are 
tried out of which methanol and chloroform was found to be suitable. 
Stationary phase: precoated silica gel GF plates  
IR SPECTROSCOPY 
(94) 
The IR spectroscopy analysis is used to determine the chemical 
functional groups present in the sample.  Different functional groups absorb 
characteristic frequencies of IR radiation. The synthesized compounds are 
suitably prepared and IR spectrum was recorded using of FT-IR 
spectrophotometry(model no: MB 3000)in the range of 4000-500cm
-1 
 by kBr 
pellet technique.  
1
H NMR SPECTROSCOPY  
Proton NMR spectra was recorded on BRUKER Advance 500 NMR 
spectrometry using the solvent Deuterated Dimethyl Sulphoxide. Chemical 
shift are reported in parts per million, relative to TMS as an internal standard.  
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MASS SPECTROSCOPY
(94)
    
The mass spectroscopy, the synthesized compound under investigation  
is bombarded with a high beam of electrons producing ionic fragments of the 
original species. The relative abundance of the fragment ion formed depends 
on the stability of ion and of the last radical.    The resulting charged particles 
are then separated according to their masses. The mass spectra was   recorded 
on a Q-Tof-Mass Spectroscopy (Q-Tof micro hybrid quadrupole time of flight 
mass spectrometer) with electro spray ionization (ESI) and in JEOL 
GCMATE II GC-MS. 
HYPHENATED TECHNIQUE (95) 
GC-MS  
The gas chromatograph coupled to a mass spectrometer, by which 
complex mixture of compounds can be separated, identified and quantified. 
GC is used to determine the purity of compounds by looking for additional 
peaks in a sample that are not present in the pure compound. The smaller 
structure have lower boiling point and will thus elute faster than those with 
higher boiling point. 
Factors affecting the separation of compounds in GC-MS 
Higher boiling point of compounds, 
Polarity  of compounds versus the polarity of stationary phases on column. 
Column  type (polar-non polar) 
Amount of material injected, 
High temperature and High flow  rate decrease the retention time, but 
also decreased the quality of separation.  
LC-MS 
Liquid chromatography with mass spectroscopy is used to characterize 
the non-volatile compounds but GC-MS is used to characterize only the 
volatile compounds.           
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BIOLOGICAL EVALUATION Anti-tubercular Activity 
There are various high throughput assays available for screening of 
new chemical entities against tuberculosis. They are: 
 Resazurin Micro plate Assay (REMA) 
 Nitrate Reductase Assay (NRA) 
 Micro plate Alamar Blue Assay (MABA) 
 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) 
 Middle Brook 7H11 Agar dilution Assay 
 Broth Micro dilution Method 
 BACTEC system 
 Luciferase Reporter Phage Assay 
THE ALAMAR BLUE ASSAY  
Alamar Blue monitors the reducing environment of the living cell. The 
active ingredient is resazurin (IUPAC name: 7-hydroxy-10-oxidophenoxazin-
10-ium-3-one), also known as diazoresorcinol, azoresorcin, resazoin, 
resazurine, which is water-soluble, stable in culture medium, is non-toxic and 
permeable through cell membranes. Continuous monitoring of cells in culture 
is therefore permitted. Growth is measured quantitatively by a visual colour 
change and the amount of fluorescence produced is proportional to the 
number of the living cells which is determined by colorimetric and 
fluorimetric methods.
(96)
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Figure10
(87)
  
 
Redox principle 
 This assay is an indirect colorimetric DST method for determining the 
MIC of TB drug strains of Mycobacterium tuberculosis. The redox indicator 
Alamar blue monitors the reducing environment of the living cell. It turns 
from blue to pink in the presence of mycobacterial growth. As the indicator 
dye accepts electrons it changes from the blue, oxidized, non fluorescent state 
to the pink, reduced, fluorescent state. The oxidation-reduction potential of 
Alamar Blue is +380 mV fore, can be reduced by NADPH ( Eo = 320 mV), 
FADH (Eo = 220 mV), FMNH (Eo = 210 mV), NADH (Eo = 320 mV), as 
well as the cytochromes (Eo = 290 mV to +80 mV). In addition to 
mitochondrial reductases, other enzymes (such as the diaphorases (EC 1.8.1.4, 
dihydrolipoamine dehydrogenase), NAD (P) H: quinine oxidoreductase (EC 
1.6.99.2) and flavin reductase (EC 1.6.99.1) located in the cytoplasm and the 
mitochondria may be able to reduce Alamar Blue. (98)  
ADVANTAGES 
 It has accurate time course measurement.  
 It has high sensitivity and linearity.  
 It involves no cell lysis.  
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 It is ideal for use with post measurement functional assay.  
 It is flexible as it can be used with different cell models.  
 It is scalable and can be used with fluorescence and/or 
absorbance based instrumentation platforms.  
 It is nontoxic, non-radioactive and is safe for the user.  
APPLICATIONS 
Especially meant for studies on Mycobacterium tuberculosis. 
Used extensively in cell viability and cytotoxicity studies. (99) 
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ACUTE TOXICITY STUDIES 
Acute toxicity describes the adverse effects of a substance that result 
either from a single exposure or from multiple exposures in a short space of 
time (usually less than 24 hours). To be described as acute toxicity, the 
adverse effects should occur within 14 days of the administration of the 
substance. 
Acute toxicity studies in animals are usually necessary for any 
compound intended for human use. The information obtained from these 
studies is useful in choosing doses for repeat-dose studies, providing 
preliminary identification of target organs of toxicity, and, occasionally, 
revealing delayed toxicity. Acute toxicity studies may also aid in the selection 
of starting doses for Phase I human studies, and provide information relevant 
to acute overdosing in humans.
(100) 
This acute toxicity study was designed as per the OECD Guidelines for 
Testing of Chemicals, Acute Oral Toxicity (Acute Toxic Class Method), 
Guideline 423. 
PRINCIPLE OF THE TEST 
The test is based on a stepwise procedure with the use of a minimum 
number of animals per step. The substance is administered orally to a group 
of experimental animals at one of the defined doses. The substance is tested 
using a stepwise procedure, each step using 3 animals of a single sex 
(normally females). Absence or presence of compound-related mortality of 
the animals dosed at one step will determine the next step, i.e.  
 No further testing is needed.
 Dosing of three additional animals, with the same dose.
 Dosing of three additional animals at the next higher or the next 
lower dose level

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DESCRIPTION OF THE METHOD:  
Experimental animals  
Healthy adult female Albino mice (14 nos.) weighing between 20-25g 
are used for the research. For all the animals, food, but not water is withheld 
overnight prior to dosing. 
Housing and lighting conditions  
The temperature in the experimental animal room is maintained at 22ºC 
(±3ºC). Although the relative humidity should be at least 30% and preferably not 
exceed 70% other than during room cleaning, the aim should be 50-60%. 
Lighting should be artificial, the sequence being 12 hours light, 12 hours dark. 
For feeding, conventional laboratory diets may be used with an unlimited supply 
of drinking water. Animals may be group-caged by dose, but the number of 
animals per cage must not interfere with clear observations of each animal
(101) 
PROCEDURE 
Administration of doses  
The synthesised compounds are administered initially at a starting dose 
of 2000mg/kg body weight in 1% CMC and observed 14 days for any 
mortality due to acute toxicity. The test substance is administered in a single 
dose by using a 19 gauge oral tube.  
Testing procedures  
The test compounds are administered to the animal to identify doses 
causing no adverse effects and doses causing major (life-threatening) toxicity. 
The use of vehicle for control groups should be considered. For compounds 
with low toxicity, maximum feasible dose should be administered.  
OBSERVATION 
The animals are observed individually after dosing once, during the 
first 30 minutes, periodically for the first 24 hours, with special attention 
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given during the first 4 hours & daily there-after, for a total of 14 days. The 
following clinical observation are made and recorded.  
Toxic Signs
Whatever a mice showed observed  any toxic signs
Body Weight
Individual body weights are recorded for all the animals once in a week.
Cage Side Observation
The faeces colour, faeces consistency, changes in skin & fur, eyes & 
mucous membrane (nasal) of the animal are observed once in a week.
Physical examination
Salivation, lacrymation, perspiration, piloerection, micturition and 
defecation. Central nervous system: Ptosis, drowsiness, gait, eye prominence, 
eyelid closure, convulsions, biting, straub’s test , motor incoordination, 
writhing, stereotypy, aggression, righting reflex, pinna reflex, corneal reflex, 
tremors and convulsions.
FIGURE 11
(101) 
 
Fig 22- OECD Guidelines for Performing Animal Toxicitystudies  
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IN VITRO ANTITUBERCULAR ACTIVITY  
MICROPLATE ALAMAR BLUE ASSAY (MABA) 
(108,109,110)
 
 The anti-mycobacterial activities of the synthesized compounds are 
determined by MABA method. The organism used  is M.tuberculosis 
H37Rv 
 Alamar blue dye is used as an indicator for the determination of viable 
cells. 
Principle 
 MABA is an indirect colorimetric Drug Susceptibility Test method for 
determining the Maximum Inhibitory Concentrations of TB drugs for strains 
of Mycobacterium tuberculosis. In this assay, the redox indicator Alamar blue 
monitors the reducing environment of the living cells. It turns from blue to 
pink in the presence of mycobacterium growth.  
Procedure 
1) The anti-mycobacterial activity of compounds are assessed against M. 
tuberculosis using Micro Plate Alamar Blue assay (MABA).  
2) This methodology is non-toxic, and uses a thermally stable reagent and 
shows good correlation with proportional and BACTEC radiometric 
method. 
3) 200μl of sterile deionized water is added to all outer perimeter wells of 
sterile 96 wells plate to minimize evaporation of medium in the test 
wells during incubation. 
4) The 96 wells plate receive 100 μl of the Middle brook 7H9 broth and 
serial dilution of compounds is placed directly on plate.  
5) The final drug  concentrations tested is 100to0.8 μg/ml.  
6) Plates are covered and sealed with film and incubated at 37ºC for five 
days. 
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7) After this time, 25μl of freshly prepared 1:1 mixture of Alamar Blue 
reagent and 10% Tween 80 is added to the plate and incubated for 24 
hrs. 
8) A blue color in the well is interpreted as no bacterial growth, and pink 
color was scored as growth. 
The MIC is defined as lowest drug concentration which prevents the 
color change from blue to pink.  
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RESULTS AND DISCUSSION 
RESULTS OF DRUG DESIGN 
DRUG LIKENESS 
 Lipinski`s rule of five of thumb to evaluate drug linkeness, or to 
determine if a chemical compound with  certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in 
humans. The rule describes molecules properties important for a drugs 
pharmacokinetics in the humans body, including their absorption, distribution, 
metabolism, and excretion(ADME).However, the rule does not predict if a 
compound is pharmacologically active. 
The rule is important for drug development where a pharmacologically 
active lead structure is optimized step-wise for increased activity and 
selectivity,as well as drug-like properties as described by Lipinski rule. The 
modification of the molecular structure often leads to drug with higher 
molecular weight, more ring, more rotatable bonds, and  higher polarity.  
Lipinski rule says that ,an orally active drug has no more than one 
violation of the following criteria:  
 Not more than 5 hydrogen bonds doners (nitrogen or oxygen atoms 
with one or more hydrogen bond) 
 Not more than 5 hydrogen bond acceptors (nitrogen or oxygen atoms)  
 A molecular weight under 500 daltons 
 A partition coefficient log p less than 5 
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LIPINSKI RULE AND SYNTHESIZED COMPOUNDS 
Compound 
Molecular 
Formula 
Molecular 
weight 
Hydrogen 
bond 
acceptor 
Hydrogen 
bond 
donor 
Partition 
coefficient 
9-F C19H14N2O 286.32 3 1 3.47 
9-DF C22H16F2N2O 362.37 5 1 5.05 
9-V C22H18N2O2 342.39 4 2 4.34 
9-S C19H14N2S 302.39 3 1 4.84 
9-PD C20H13N3 295.33 3 1 3.52 
INSILICO DRUG LIKENESS PREDICTION 
SAMPLE CODE-9F 
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SAMPLE CODE-9DF 
 
 
SAMPLE CODE-9V 
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SAMPLE CODE-9S 
 
 
SAMPLE CODE-9P 
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SAMPLE CODE-9DM 
 
 
SAMPLE CODE-9PD 
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SAMPLE CODE-CN 
 
 
DOCKING STUDIES 
Morethan 200 scaffolds were docked against the MTB enzyme L,D-
Transpeptidase (4GSU) by using Argus lab 4.0.1 software. The best docking 
Score -10 TO -15 and good interaction molecules are selected and screened.I 
have selected 8 compounds for synthesis which is having docking energy is -
10 to -15. The compounds were also docked against the critical enzyme of the 
mycobacterium tuberculosis Diaminopimelate epimarase (dapF) and UDP-N-
acetyl muramate-L-alanine ligase. 
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The docking score of the 3 target enzymes are listed bellow  
Compounds 
L,D-
Transpeptidase 
Diaminopimelate 
epimarase 
UDP-N-acetyl 
muramate 
–L-alanine ligase 
9-F -9.247kcal/mol -7.62kcal/mol -8.90kcal/mol 
9-DF -10.62kcal/mol -8.53kcal/mol -9.94kcal/mol 
9-V -10.95kcal/mol -7.30kcal/mol -7.34kacl/mol 
9-S -9.985kcal/mol -7.81kcl/mol -8.21kcal/mol 
9-P -8.63kcal/mol -8.96kcal/mol -9.96kcal/mol 
9-DM -10.12kcal/mol -8.46kcal/mol -8.90kcal/mol 
9-PD -9.873kcal/mol -7.71kcal/mol -7.62kcal/mol 
9-CN -11.42kcal/mol -8.62kocal/mol -8.62kcal/mol 
Table 1 : Docking Score and View 
Compound   
code 
Structure 
Docking 
Score 
Docking view 
 9-F 
 
NHN
O
 
 
-
9.247Kca/mol 
 
9-DF  
NHN
F
F
H3CO
 
-
10.62kcal/mol 
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Compound   
code 
Structure 
Docking 
Score 
Docking view 
9-V 
NHN
OH
OCH3
 
 
-
10.95kcal/mol 
 
9-S 
NHN
S
 
 
-
9.985kcal/mol 
 
9-P 
NHN
NH
 
 
-
8.637kcal/mol 
 
9-DM 
NHN
N
CH3CH3
 
 
-
10.12kcal/mol 
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Compound   
code 
Structure 
Docking 
Score 
Docking view 
9-PD 
NH N
N
 
 
-
9.873kcal/mol 
 
9-CN 
NNH
Cl
O2N
 
-
11.42kcal/mol 
 
 
Table 2 : 4GSU Interaction with Ligand 
Sample code-9F Sample code-9DF 
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Sample code-9-v Sample code-9s 
  
Sample code-9P Sample code-9DM 
  
Sample code-9PD Sample code-9CN 
  
 
Results & Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.63 
TABLE 3 : COMPOUNDS DOCKED AGAINST THE PROTEIN 4IKO 
Compound   
code 
Structure Docking 
Score       
Docking view 
9-F 
NHN
O
 
-
7.62kcal/mol 
 
9-DF 
NHN
F
F
H3CO
 
-
8.53kcal/mol 
 
9-V 
NHN
OH
OCH3
 
-
7.30kcal/mol 
 
9-S 
NHN
S
 
-
7.81kcal/mol 
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9-P 
NHN
NH
 
-
8.96kcal/mol 
 
9-DM 
NHN
N
CH3CH3
 
-
8.46kcal/mol 
 
9-PD 
NH N
N
 
-
7.71kcal/mol 
 
9-CN 
NNH
Cl
O2N
 
-
8.62kcal/mol 
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Table 4: 4IKO Interaction with Ligand 
Sample code-9F Sample code-9DF 
 
 
Sample code-9-v Sample code-9s 
  
Sample code-9P Sample code-9DM 
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Sample code-9PD Sample code-9CN 
  
TABLE 5 :COMPOUNDS DOCKED AGAINST THE PROTEIN 2FOO 
Compound   
code 
Structure 
Docking 
Score 
Docking view 
9-F 
NHN
O
 
-8.90kcal/mol 
 
9-DF 
NHN
F
F
H3CO
 
-9.94kcal/mol 
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9-V 
NHN
OH
OCH3
 
-
7.34kcal/mol 
 
9-S 
NHN
S
 
-8.21kcl/mol 
 
9-P 
NHN
NH
 
-9.96kcl/mol 
 
9DM 
NHN
N
CH3CH3
 
-
8.90kcal/mol 
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9-PD 
NH N
N
 
-
7.62kcal/mol 
 
9-CN 
NNH
Cl
O2N
 
-
7.62kcal/mol 
 
TABLE 6 :2FOO INTRACTION WITH LIGAND 
Sample code-9F Sample code-9DF 
  
Sample code-9-v Sample code-9s 
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Sample code-9P Sample code-9DM 
  
Sample code-9PD Sample code-9CN 
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RESULTS OF SYNTHESIZED COMPOUNDS 
 The synthetic route was preferred by conventional method. The 
reaction was carried out by using 1 mole of phenanthrene 9,10 Dione,1mole 
of substituted aromatic aldehyde and 2 moles of ammonium acetate, poly 
ethylene glycol which is acts as catalyst the mixture is refluxed. This 
synthesis is involves modified palnour  reaction leading to format ion of 
Benzodiazole nucleus. One mole of benzil used as a another reactant this is 
leads to formation of imidazole nucleus.  
CHARACTERISATION 
The synthesized compounds were subjected to purification by 
recrystallization and TLC. The melting point of the synthesized compounds 
was founded. The characterization was carried out using sophisticated 
instruments like IR, NMR, and Mass spectroscopy and characteristic 
properties through the aid of computer software.  
INFRARED ABSORPTION SPECTROSCOPY 
IR spectrum of synthesized compounds the following functional groups 
like Ar-CH, NH, NO2,C=NH,C=C,C-O-C-CH3 can be ascertained. 
The absorption band of the parent reactants are as follows  
 Aldehyde    : 2830 - 2695cm-1 
 Ketone        : 1710 – 1720cm-1 
 Amines       : 3000-3300cm-1 
The IR spectra is showed the absence of parent groups and the 
presence of   a new functional groups are C=NH and NH2 stretching are 
formed. For all the synthesized compounds 9-F,9-DF,9-V,9-S,9-P,9-DM,9-CN 
the absorption band for C=NH stretching at 2347.47cm
-1
 are obtained. 
 IR absorption of the synthesized compounds 9-DM showed the 
presence of aliphatic C-H stretching vibration between 2960-2916cm
-
1
,For all the synthesized compounds showed the presence of NH 
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stretching vibration between 3440-3390cm
-1
,aromatic CH stretching 
vibration between 3080-3060 cm
-1
, C-N stretching vibration between 
1220-1280 cm
-1
are obtained. 
 The absorption band for 9-CN compound showed the strong band at 
1342cm
-1
 was indicate the presence of nitro group.  
1
H NMR SPECTRA 
The number of signals in an NMR spectrum denotes the number of the 
set of equivalent protons in a molecule . The position of the signals help us to 
know the nature of protons viz, aromatic, heteroaromatic, aliphatic, vinyl C -H 
groups. 
NMR Data In δ scale pertaining to the synthesized compounds 
The 
1
H NMR spectral data of all the synthesized compounds are in 
conformity with the structure assigned. A singlet at 9.74-10.02 was observed 
for all compounds conforming the presence of N-H proton. High deshielding 
was due to the presence of electro negative nitrogen atom and additional 
conjugation. So lesser value of applied field is needed to resonate the proton. 
In general protons adjacent to N-are strongly deshielded. All the compounds 
showed multiplet and doublet signals for the presence of aromatic protons 
between (6.20-8.59) δppm and heteroaromatic protons between (6.20 -8.3) 
δppm. 
GAS CHROMATOGRAPHY-MASS SPECTROMETRY 
GC is used to determine the purity of compounds by looking for 
additional peaks in a sample that are not present in the pure compound. The 
smaller structure have lower boiling point and will thus elute faster than those 
with higher boiling point. 
The synthesized compound of 9-F is 100% Purity ,which is having 
signal at m/e 285.35 is molecular ion peak. There is no additional peak 
present in this compound. The synthesized compound of 9-DF is 96% purity, 
which is having signal at m/e 361.37 is the molecular ion peak and also the 
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base peak. molecular ion peak can be a base peak but base peak should not be 
a molecular ion peak.    
GENERAL MASS SPECTRAL DETAILS OF THE  SYNTHESIZED  
COMPOUND 
The synthesized compounds are undergoing two types of cleavage namely 
1) HOMOLYTIC 
2) HETEROLYTIC  
Under hemolytic cleavage the compound basically undergoes mode II 
cleavage. In all the synthesized compounds hetero atom is singly bonded 
carbon atom, So parent/molecular ion is formed by removal of one electron 
from the molecule (mode I)  
Heterolytic cleavage is the most important fragmentation pattern 
observed in the synthetic compounds. The cleavage of C-N bond is more difficult 
than C-C bond. So the positive charge is carried by carbon and not heteroatom. In 
the set of all synthetic compounds having a different molecular ion of mass 9-
F=286.32,9DF=362.37 was found which might be due to C-N cleavage. 
TABLE 7 : MOLECULAR WEIGHT OF SYNTHESIZED 
COMPOUNDS 
NAME OF 
COMPOUNDS 
CALCULATED         
MASS 
ACTUAL 
MASS 
9-F 286.32g/mole 286.22g/mole 
9-DF 362.37g/mole 362.18g/mole 
9-V 342.39g/mole 342.22g/mole 
9-S 302.39g/mole 302.06g/mole 
9-P 285.34g/mole 285.28g/mole 
9-DM 339.43g/mole 339.48g/mole 
9-PD 295.37g/mole 296.12 g/mole 
9-CN 373.79g/mole 374.02g/mole 
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RESULTS OF LC-MASS 
Liquid chromatography with mass spectroscopy was used to 
characterize the non-volatile compounds. The synthesized compounds is 
characterized in lc-ms. These are compounds (9-v,9-s,9-p,9-cn) showed 99% 
purity with molecular ion peek.             
DISCUSSION  
 Fifty compounds were selected using chemsketch and docked against 
the target enzyme L,D-Transpeptidase-2 .The top 10 compounds with 
good G-score and ligand interaction and least toxicity were selected 
and synthesized. 
 The synthesized compounds are characterized using IR, GC-MASS, 
LC-MASS, NMR spectroscopy. 
 The synthesized compound of 9-DF was found to be 100% purity and 
9-DF is 95% purity was determined by GC-MS spectroscopy. 
 All the other compounds 9-v,9-s,9-p,9-dm,9-pd,9-cn was found to be 
99% purity. 
 All the compounds were tested for the invitro anti-tb activity. The 9-
DF compound was found to be the most sensitive at the least 
concentration 1.6µg/ml and compounds 9-s,9-v,9-p,9-dm,9-pd,9-cn 
showed minimum inhibitory concentration at 12.5µg/ml.  
 Acute Toxicity Studies 
There was no death no death of any animal in the acute toxicity study 
performed  by the ICH guidelines over 14 days period. The animals showed 
no significant toxicity. 
Mechanism Of Action 
The L,D-Transpeptidase-2 enzyme catalyse the formation of 
peptidoglycan cross-links of the mycobacterium tuberculosis cell wall and 
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facilitates the resistance against classical β-lactams. The synthesized 
compounds inactivate the L,D-Transpeptidse-2 enzyme. 
The compounds were also docked against the following critical enzyme 
of the mycobacterium tuberculosis.  
 Diaminopimelate epimarase (dapF).  
 UDP-N-acetyl muramate-L-alanine ligase  
 If it is clear by the docking studies that the synthesized compounds act 
by the inhibiting L,D-Transpeptidase. The compounds 9-F,9-DF,9-V,9-
DM,9-CN rather than the enzymes Diaminopimelate epimarase (dapF). 
UDP-N-acetyl muramate-L-alanine ligase. 
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PRODUCT PROFILE 
SAMPLE CODE:9-F 
NHN
O
 
IUPAC Name : 2-(furan-2-yl)-4,5-diphenyl-1H-imidazole 
Molecular Formula  : C19H14N2O 
Formula Weight  : 286.32g/mol 
Appearance  : black colour crystals   
Melting Point  : 308ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 95%  
Composition  : C[79.70%], H[4.93%], N[9.78%], O[5.59%] 
Molar Refractivity  : 84.85±0.3cm3  
Molar Volume  : 239.6±3.0cm3  
Parachor  : 635.0±4.0cm3 
Index of Refraction  : 1.626±0.02  
Surface Tension  : 49.3±3.0 dyne/cm  
Density  : 1.194±0.06g/cm3 
Polarizability  : 33.63±0.510-24cm
3 
Monoisotopic Mass  : 286.110613 Da 
Nominal Mass  : 286 Da 
Average Mass  : 286.3273 D
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IR Spectrum: 9-F 
 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
6 
7 
3062.13cm-1 
1532.51cm-1 
1229.67cm-1 
2348.83cm-1 
1094.65cm-1 
1027.14cm-1 
3425.72cm-1 
-CH Stretching 
-C=C Stretching 
-C-C Stretching 
-C=N stretching 
-C-N Stretching 
-C-O Stretching 
-N-H Stretching 
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GC-MS Spectrum: 9-F 
 
 
Results & Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.78 
H1 NMR Spectrum:-9F 
 
 
S.No δ value Nature of Peak Number of Protons 
1 δ2.4 Doublet 2 proton 
2 δ 3.3 Singlet 1 proton 
3 δ 8.9-9.1 Doublet 2 proton 
4 δ 6.7-8.6 Multiplet 9protons 
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SAMPLE CODE: 9-DF 
NHN
F
F
H3CO
 
IUPAC Name : 2-(2,3-difluoro-6-methoxyphenyl)-4,5-diphenyl-1H-
imidazole 
Molecular Formula  : C22H16F2N2O 
Formula Weight  : 362.37g/mol  
Appearance  :  Yellow colour solid 
Melting Point  : 310ºC 
Solubility  :  Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 95%  
Composition  : C[79.92%], H[4.45%], F[10.49],N[7.73%], 
O[4.42%] 
Molar Refractivity  : 99.21±0.3cm3  
Molar Volume  : 289±3.0cm3  
Parachor  :  752.0±4.0cm3 
Index of Refraction  : 1.601±0.02  
Surface Tension  : 45.6±3.0 dyne/cm  
Density  :  1.252.±0.06g/cm3 
Polarizability  : 39.33±0.510-24cm
3 
Monoisotopic Mass  : 362.12307 Da 
Nominal Mass  : 362 Da 
Average Mass  : 362.372 D 
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IR Spectrum: 9-DF 
 
S.NO WAVE NUMBER (cm-1)  FUNCTIONL GROUPS  
1 
2 
3 
4 
5 
6 
7 
3068.88cm
-1 
2348.43cm
-1 
1496.83cm
-1 
1248.96cm
-1 
3422.83cm
-1 
2927.10cm
-1 
1017.64cm
-1 
-CH Stretching 
-C=N Stretching 
-C=C Stretching 
-C-N Stretching 
-N-H Stretching 
-C-OCH3 Stretching 
-C-F Stretching 
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GC-MS Spectrum: 9-DF 
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H1 NMR Spectrum:-9DF 
 
 
S.No δ value Nature of Peak  Number of Protons  
1 δ2.4 singlet 1 proton 
2 δ 3.5 singlet 1 proton 
3 δ 4 singlet 3 proton 
4 δ 7-9.1 Multiplet 11protons 
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SAMPLE CODE: 9-V 
NHN
OH
OCH3
 
IUPAC Name : 2-(4-hydroxy-3-methoxyphenyl)-4,5-diphenyl-1H-
imidazole 
Molecular Formula  : C22H18N2O2 
Formula Weight  : 342.39g/mol  
Appearance  : light grean colour solid 
Melting Point  : 310ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 98%  
Composition  : C[77.17%], H[5.30%], N[8.18], O[9.35%] 
Molar Refractivity  :  101.11±0.3cm3  
Molar Volume  : 279.2±3.0cm3  
Parachor  : 752.77±4.0cm3 
Index of Refraction : 1.643±0.02  
Surface Tension : 52.7±3.0 dyne/cm  
Density : 1.226.±0.06g/cm3 
Polarizability : 40.08±0.510-24cm3 
Monoisotopic Mass : 342.136828 Da 
Nominal Mass : 342 Da 
Average Mass : 342.3905 Da 
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IR Spectrum: 9-V 
 
 
S. 
NO 
WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 3075.63cm-1 -CH Stretching 
2 1516.11cm-1 -C=C Stretching 
3 1276.93cm-1 -C-N Stretching 
4 2347.47cm-1 -C=N Stretching 
5 3623.44cm-1 -OH Stretching 
6 2928.07cm-1 -C-OCH3 Stretching 
7 3393.09cm-1 -N H Stretching 
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LC-MS Spectrum: 9-V 
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H1 NMR Spectrum:-9V 
 
 
S.No δ value Nature of Peak Number of Protons 
1 δ 1.9 singlet 1 proton 
2 δ 2.5 singlet 1 proton 
3 δ3.5 singlet 1 proton 
4 δ  4 singlet 3protons 
5 δ 7-8.2 multiplet 7 protons 
6 δ 8.8-10 multiplet 5protons 
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SAMPLE CODE: 9-S 
NHN
S
 
IUPAC Name : 4,5-diphenyl-2-(thiophen-2-yl)-1H-imidazole 
Molecular Formula : C19H14N2S 
Formula Weight  : 302.39g/mol  
Appearance  : light yellow colour solid 
Melting Point  : 320ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 98%  
Composition  : C[75.47%], H[4.67%], N[9.26], S[10.60%] 
Molar Refractivity  : 90.93±0.3cm3  
Molar Volume  : 246.373±3.0cm3  
Parachor  : 604.2±4.0cm3 
Index of Refraction  : 1.660±0.02  
Surface Tension  : 52.873±3.0 dyne/cm  
Density  : 1.227.±0.06g/cm3 
Polarizability  : 36.0570.510±0.510-24cm3 
Monoisotopic Mass  : 302.087768 Da 
Nominal Mass  : 302 Da 
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IR Spectrum: 9-S 
 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
6 
3089.13cm-1 
1634.74cm-1 
2347.47cm-1 
1226.79cm-1 
3412.22cm-1 
731cm-1 
-CH Stretching 
-C=C Stretching 
-C=N Stretching 
-C-N stretching 
-N-H Stretching 
-C-S Stretching 
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LC-MS Spectrum: 9-S 
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H1 NMR Spectrum:-9S 
 
 
S.No δ value Nature of Peak Number of Protons 
1 δ2.4 singlet 1 proton 
2 δ 3.5 singlet 1 proton 
3 δ 7.4 singlet 1 proton 
4 δ 7.5-9 Multiplet 11protons 
 
Results & Discussion 
College of Pharmacy, MMC, Chennai-3. Page No.91 
SAMPLE CODE: 9-P 
NHN
NH
 
IUPAC Name  : 4,5-diphenyl-2-(1H-pyrrol-2-yl)-1H-imidazole 
Molecular Formula  : C19H15N3 
Formula Weight  : 285.34g/mol  
Appearance  : black colour solid 
Melting Point  : 305ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 96%  
Composition  : C[79.98%], H[5.30%], N[14.73%],  
Molar Refractivity  : 86.98±0.3cm3  
Molar Volume  : 235.1±3.0cm3  
Parachor  : 640.7±4.0cm3 
Index of Refraction  : 1.661±0.02  
Surface Tension  : 55.17±3.0 dyne/cm 
Density  : 1.213.±0.06g/cm3 
Polarizability  : 34.48±0.510-24cm3 
Monoisotopic Mass  : 285.126597 Da 
Nominal Mass  : 285 Da 
Average Mass  : 285.3425 Da 
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IR Spectrum: 9-P 
 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
3081.42cm-1 
1525.76cm-1 
2349.4cm-1 
1242.21cm-1 
3204.87cm-1 
-CH Stretching 
-C=C Stretching 
-C=N Stretching 
-C-N stretching 
-NH stretching 
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LC-MS Spectrum: 9-P 
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H1 NMR Spectrum:-9P 
 
S.No δ value Nature of Peak Number of Protons 
1 δ1.9 singlet 1 proton 
2 δ 2.6 singlet 1 proton 
3 δ 3-4 singlet 1 proton 
4 δ 6.3 singlet 1 protons 
5 δ 7.2 singlet 2 protons 
6 δ 7-9 multiple 11 protons 
7 δ 11.8 Singlet 1 proton 
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SAMPLE CODE: 9-DM 
NHN
N
CH3 CH3
 
IUPAC Name : 4,5-diphenyl-2-(4-dimethylamino-1-phenyl)-1H-
imidazole 
Molecular Formula  : C23H21N3  
Formula Weight  : 339.432g/mol  
Appearance  : Brown colour solid 
Melting Point  : 335ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 98%  
Composition  : C[81.38%], H[6.24%], N[12.38%],  
Molar Refractivity  : 106.86±0.3cm3  
Molar Volume  : 294.8±3.0cm3  
Parachor  : 783.1±4.0cm3 
Index of Refraction  : 1.644±0.02  
Surface Tension  : 49.7±3.0 dyne/cm  
Density  : 1.151.±0.06g/cm3 
Polarizability  : 42.36±0.510-24cm3 
Monoisotopic Mass  : 339.173548 Da 
Nominal Mass  : 339 Da 
Average Mass  : 339.4329 Da 
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IR Spectrum: 9-DM 
 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
3064.06cm-1 
2916.49cm-1 
1184.34cm-1 
2347.47cm-1 
1606.77cm-1 
-CH Stretching 
-C-H Stretching 
-C-N Stretching 
-C=N stretching 
-C=C Stretching 
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LC-MS Spectrum: 9-DM 
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H1 NMR Spectrum:-9DM 
 
S.No δ value Nature of Peak Number of Protons 
1 δ1.8 singlet 1 proton 
2 δ 2.5 singlet 2 proton 
3 δ3 singlet 6 proton 
4 δ3.2-4 singlet 1protons 
5 δ7 singlet 1 protons 
6 δ7.5-9 multiplet 10protons 
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SAMPLE CODE: 9-PD 
NH N
N
 
IUPAC Name  : 4-(4,5-diphenyl-1H-imidazol-2-yl)pyridine 
Molecular Formula  : C20H13N3 
Formula Weight  : 295.37g/mol  
Appearance  : dark yellow colour solid  
Melting Point  : 315ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 97%  
Composition  : C[81.34%], H[4.44%], N[14.25],  
Molar Refractivity  : 94.98±0.3cm3  
Molar Volume  : 221.8±3.0cm3  
Parachor  : 640.0±4.0cm3 
Index of Refraction  : 1.801±0.02  
Surface Tension  : 62.2±3.0 dyne/cm  
Density  : 1.331±0.06g/cm3 
Polarizability  : 37.65±0.510-24cm3 
Monoisotopic Mass  : 295.110947 Da 
Nominal Mass  : 295 Da 
Average Mass  : 295.3373 Da 
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IR Spectrum: 9-PD 
 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
3048.62cm-1 
1528.65cm-1 
2346.51cm-1 
1219.06cm-1 
3422.83cm-1 
-CH Stretching 
-C=C Stretching 
-C=N Stretching 
-C-N stretching 
-N-H Stretching 
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LC-MS Spectrum: 9-PD 
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H1 NMR Spectrum:-9PD 
 
 
S.No δ value Nature of Peak Number of Protons 
1 δ2.5 singlet 1 proton 
2 δ 3.5 singlet 1 proton 
3 δ4 singlet 1 proton 
4 δ7.6-9 Multiplet 10 protons 
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SAMPLE CODE: 9-CN 
NNH
Cl
O2N
 
IUPAC Name  : 4,5-diphenyl-2-(2-chloro-5-nitro-1-phenyl)-1H-
imidazole 
Molecular Formula  : C21H12CLN3O2  
Formula Weight  : 373.7924g/mol  
Appearance  : light green colour 
Melting Point  : 325ºC 
Solubility  : Chloroform, Methanol, Dimethyl Sulfoxide  
Percentage Yield  : 97%  
Composition  : C[67.48%], H[3.24%], CL[9.48%],N[11.24%],  
Molar Refractivity  : 108.337±0.3cm3  
Molar Volume  : 252.4±3.0cm3  
Parachor  : 737.27±4.0cm3 
Index of Refraction : 1.804±0.02  
Surface Tension  : 72773.0±3.0 dyne/cm  
Density  : 1.480.±0.06g/cm3 
Polarizability  : 42.9470.510±0.510-24cm3 
Monoisotopic Mass : 373.061804 Da 
Nominal Mass : 373 Da 
Average Mass : 373.7919 Da 
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IR Spectrum 9-CN 
 
S.NO WAVE NUMBER (cm-1) FUNCTIONL GROUPS 
1 
2 
3 
4 
5 
6 
3085.27cm-1 
1524.79cm-1 
1438.96cm-1 
2347.47cm-1 
1241.25cm-1 
3438.26cm-1 
-CH Stretching 
-C-NO2 Stretching 
-C=C Stretching 
-C=N stretching 
-C-N Stretching 
-NH Stretching 
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LC-MS Spectrum: 9-CN 
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H1 NMR Spectrum:-9CN 
 
 
S.No δ value Nature of Peak Number of Protons 
2 δ 3.5 singlet 1 proton 
3 δ7.6-8 multiplet 6 proton 
4 δ8.5-9.2 Multiplet 6 protons 
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Biological Evaluation 
Anti-TB Results 
Sl. 
No 
samples 
100 
μg/ml 
50 
μg/ml 
25 
μg/ml 
12.5 
μg/ml 
6.25 
μg/ml 
3.12 
μg/ml 
1.6 
μg/ml 
0.8 
μg/ml 
1 9-F S S S S R R R R 
2 9-DF S S S S S S S R 
3 9-V S S S S R R R R 
4 9-S S S R R R R R R 
5 9-P S S R R R R R R 
6 9-DM S S R R R R R R 
7 9-PD S S R R R R R R 
8 9-CN S S R R R R R R 
Note: S-Sensitive  
R-Resistant  
Strain used: M.tuberculosis (H37 RV strain). 
Here are the standard values for the Anti-Tb test which was 
performed.  
 Pyrazinamide- 3.125μg/ml.   
 Streptomycin- 6.25μg/ml.   
 Ciprofloxacin- 3.125μg/ml. 
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SAMPLE DRUG PHOTOGRAPH 
Sl. 
No 
samples 
100 
μg/ml 
50 
μg/ml 
25 
μg/ml 
12.5 
μg/ml 
6.25 
μg/ml 
3.12 
μg/ml 
1.6 
μg/ml 
0.8 
μg/ml 
1 9-F 
 
 
 
 
 
2 9-DF 
3 9-V 
4 9-S 
5 9-P 
6 9-DM 
7 9-PD 
8 9-CN 
STANDARD DRUG PHOTOGRAPH 
 
Toxicity Studies  
Toxicity predicted by the OSIRIS Property Explorer the online 
software of Thomas Sander, Actelion Pharmaceuticals Ltd., Gewerbestrasse 
16, and 4123 Allschwil, Switzerland. The OSIRIS Property Explorer shown in 
this page is an integral part of Actelion's (1) inhouse substance registration 
system. It lets you draw chemical structures and calculates on-the-fly various 
drug-relevant properties whenever a structure is valid. Prediction results are 
valued and color coded. Properties with high risks of undesired effects like 
Results & Discussion 
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mutagenicity or a poor intestinal absorption are shown in red. Whereas a 
green color indicates drugconform behavior. 
Sample code : 9-F 
 
Sample code : 9-DF 
 
Sample code: 9-V 
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Sample code: 9-S 
 
    Sample code: 9P 
 
Sample code: 9-DM 
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Sample code: 9-PD 
 
Sample code: -9-CN 
 
PHARMACOLOGICAL STUDIES 
ACUTE TOXICITY STUDY 
Behavioural and physical observation of chemically synthesized 
compounds treated mice (2000mg/kg body weight)  
Results & Discussion 
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TABLE : 8 Observation of acute toxicity study 
OBSERVATION 
S. 
No 
Parameter 30min 4hr 24hrs 48hrs 
7th 
Day 
14th 
Day 
1. Sedation Absent Absent Absent Absent Absent Absent 
2. Excitation Absent Absent Absent Absent Absent Absent 
3. Jumping Normal Normal Normal Normal Normal Normal 
4. Writhing Absent Absent Absent Absent Absent Absent 
5. Piloerection Absent Absent Absent Absent Absent Absent 
6. Stereotypy Absent Absent Absent Absent Absent Absent 
7. Scratching Normal Normal Normal Normal Normal Normal 
8. Grooming Normal Normal Normal Normal Normal Normal 
9. Aggression Absent Absent Absent Absent Absent Absent 
10. Ptosis Absent Absent Absent Absent Absent Absent 
11. Exophthalmia Absent Absent Absent Absent Absent Absent 
12. Loss of righting 
reflux 
Absent Absent Absent Absent Absent Absent 
13. Loss o pinel 
reflx 
Absent Absent Absent Absent Absent Absent 
14. Loss of corneal Absent Absent Absent Absent Absent Absent 
15. Salivation Absent Absent Absent Absent Absent Absent 
16. Lacrimation Absent Absent Absent Absent Absent Absent 
17. Skin and fur Normal Normal Normal Normal Normal Normal 
18. Color of 
the eye 
Normal Normal Normal Normal Normal Normal 
19. Tremors Absent Absent Absent Absent Absent Absent 
20. Diarrhoea Absent Absent Absent Absent Absent Absent 
21. Coma Absent Absent Absent Absent Absent Absent 
22. Straub’s tail test Absent Absent Absent Absent Absent Absent 
23. Inflammation Absent Absent Absent Absent Absent Absent 
24. Gnawing Normal Normal Normal Normal Normal Normal 
25. Urination Normal Normal Normal Normal Normal Normal 
The results of acute toxicity study are shown in table. There were no 
morbididity and mortality observed  for chemically synthesized compounds 
treated animals upto  2000mg/kg.  
Future Scope of Study 
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FUTURE SCOPE OF STUDY 
The synthesized compounds should significant anti-tubercular activity 
in MABA assay method. Hence the anti-tubercular study would deserve for 
further investigation of in-vivo anti-tubercular studies. 
Summary & Conclusion 
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SUMMARY AND CONCLUSION  
 L, D-Transpeptidase-2 (4GSU), a critical enzyme for the cell wall 
synthesis of Mycobacterium tuberculosis was chosen for study after 
review of literature. 
 Candidate molecules were designed and docked against 4GSU protein 
using Argus lab 4.0software. 
 Molecules with good Docking score (lower binding energy) and 
interactions were shortlisted for synthesis. The reaction conditions 
were optimized. 
 The selected molecules were subjected to Toxicity prediction 
assessments by OSIRIS
® 
software. The results are color coded as green 
color which confirms the drug likeness.  
 Compounds were synthesized by conventional method and labeled as 
9-F,9-DF,9-V,9-S,9-P,9-DM,9-PD,and 9-CN.  
 Purity of the synthesized compounds was ensured by repeated 
recrystallization. Further the compounds were evaluated by TLC and 
Melting point determination. 
 The characterization of the synthesized compounds was done using 
Infra-red, Nuclear Magnetic Resonance (H1 NMR) and Mass 
spectroscopic methods (LC-MS, GC-MS) 
 The pure compounds were screened for In-vitro Anti- tubercular 
activity by Micro plate Alamar Blue Assay (MABA). All compounds 
showed a significant anti-mycobacterium activity. 
 The synthesized compounds were active at 1.6 - 50μg/ml, which were 
comparable into the known anti-TB drugs: Pyrazinamide - 3.125μg/ml, 
Ciprofloxacin - 3.125μg/ml and Streptomycin - 6.25μg/ml 
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CONCLUSION 
 Our work concludes that our synthesized molecules are effective in 
inhibiting the target enzyme L,D-Transpeptidase 2, which is important 
for the growth of Mycobacterium tuberculosis Cell wall.  
 All the 8 compounds gave Docking score between -8.20 to -
11.42kcal/mol. Pyrazinamide gave Docking score of -5.6 for 4GSU, 
Streptomycin gave Docking score of -7.4 for 4GSU and Ciprofloxacin 
gave Docking score of -5.9 for 4GSU. There is correlation between the 
score and activities of all the 8 compounds which were tested and 
compared with the standard drugs. This goes to prove that 4GSU is a 
critical enzyme for anti-mycobacterial activity.  
 The minimum inhibitory concentration of the 8 synthesized compounds 
against H37RV ranged from 12.5 to 1.5.μg/ml. Which is better 
compared to that of the certain known Anti-TB agents Pyrazinamide- 
3.125μg/ml, Ciprofloxacin- 3.125μg/ml and Streptomycin- 6.25μg/ml. 
_ Further structural refinement to the structure of the synthesized 
compounds is expected to yield promising molecules against the 
pathogen Mycobacterium tuberculosis.  
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